Health Innovations Pharmacy Recalls Verapamil HCl 15% Topical Cream
Health Innovations Pharmacy is recalling Verapamil HCl 15% Topical Cream due to lack of assurance of sterility and stability data.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the source text explicitly states that the quality control issues present a risk to sterility and quality assurance, which fits the criteria for a high-risk product where injury has not yet been reported.
Plain-English summary
Health Innovations Pharmacy, Inc is recalling Verapamil HCl 15% Topical Cream. The recall was initiated because of recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.
The source text indicates that the lack of assurance of sterility and stability data does not support the product's expiry. All lots of the product are affected. The distribution pattern is listed as NC.
Consumers should stop using the product and contact the recalling firm for further instructions.
The recalled product
- Product
- Verapamil HCl 15% Topical Cream, Health Innov Pharmacy, 295 Pinehurst Ave, Southern Pines, NC 28387, (910) 246-5155
- Manufacturer
- Health Innovations Pharmacy, Inc
- Category
- Drug — Topical Cream
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 65 recalled by Health Innovations Pharmacy, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 65 products in this recall →Related recalls
Same manufacturer · Health Innovations Pharmacy, Inc
See all →- ModerateCarvedilol 1.25 mg/mL Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighProgest Cream Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighHealth Innovations Pharmacy Recalls Phospholine Iodide Eye Drops
FDA (Drugs) · 2015-05-20
- HighNortriptyline Suspension Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighHealth Innovations Pharmacy Recalls Naltrexone Capsules Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
Same hazard · sterility risk
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereFDA Recalls Rohto Dry-Aid Eye Drops Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighMedline Medical Procedure Kits Recalled for High Endotoxin Levels
FDA (Devices) · 2026-05-06
- HighCook Medical tracheostomy introducer sets labeled with overstated expiration dates
FDA (Devices) · 2026-04-15
Similar recalls
- ModerateVerapamil HCl USP Recalled for Missing Stability Data and Controls
FDA (Drugs) · 2018-02-28
- SevereNatures Pharmacy Recalls Hydroxocobalamin Injections Due to Sterility Concerns
FDA (Drugs) · 2014-03-12
- SevereWestern Drug Recalls Verapamil Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereMethylcobalamin Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
- SevereNovarel Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
- HighCeftazidime Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01